Papillary Thyroid Cancer Clinical Trial
Official title:
The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience
Verified date | July 2020 |
Source | Tel-Aviv Sourasky Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background After diagnosing well-differentiated thyroid cancer (WDTC), careful assessment of
the risk for disease-specific recurrence is essential for deciding between partial (low risk)
and completion (high risk) thyroidectomies. Patients' preoperatively determined risk levels
are re-stratified according to surgical and final histopathological findings. The American
Thyroid Association 2015 guidelines suggest that patients with WDTC between 1-4 cm in size
and without suspicious features may be suitable candidates for partial thyroidectomy. The
incidence and clinical implications of high-risk features discovered postoperatively in
patients with preoperatively determined low-risk WDTC have not been previously reported.
Methods All thyroidectomies performed between 2006-2018 in the Tel Aviv Sourasky Medical
Center were included. Pre- and postoperative risk stratifications were performed, and the
rate of completion thyroidectomy was determined. Patients with 1-4 cm WDTC without evidence
of positive cervical lymph nodes, invasion to adjacent structures, or high-risk cytology were
considered at low risk for disease-specific recurrence and therefore suitable for lobectomy.
Status | Completed |
Enrollment | 301 |
Est. completion date | January 1, 2020 |
Est. primary completion date | January 1, 2018 |
Accepts healthy volunteers | |
Gender | All |
Age group | 38 Years to 61 Years |
Eligibility |
Inclusion Criteria: - All patients who underwent thyroid surgery (partial and total) between 2006-2018 at Tel Aviv Sourasky Medical Center (TASMC) were included Exclusion Criteria: - Patients with evidence of cervical lymph node metastasis, other malignancies, adverse imaging features (i.e., extracapsular spread of thyroid malignancy, vocal cord paralysis or immobility in physical examination) were excluded from the study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Tel-Aviv Sourasky Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | disease-specific recurrence | WDTC recurrence | 2006-2018 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01441154 -
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
|
||
Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT03469011 -
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
|
Phase 1 | |
Recruiting |
NCT05752669 -
Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.
|
||
Recruiting |
NCT04076514 -
The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma
|
||
Completed |
NCT06439745 -
More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
|
||
Active, not recruiting |
NCT01723202 -
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT05500508 -
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02568267 -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
|
Phase 2 | |
Unknown status |
NCT02140476 -
Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy
|
N/A | |
Recruiting |
NCT06286631 -
Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale
|
||
Completed |
NCT06325787 -
Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma
|
N/A | |
Terminated |
NCT01974284 -
Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma
|
N/A | |
Active, not recruiting |
NCT00984191 -
Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid
|
N/A | |
Active, not recruiting |
NCT04731467 -
A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05668962 -
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
|
Phase 2 | |
Completed |
NCT02178345 -
Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer
|
||
Not yet recruiting |
NCT06133374 -
Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples
|
||
Completed |
NCT03470259 -
Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging
|
Phase 1 | |
Active, not recruiting |
NCT04129411 -
Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
|
N/A |